Form 4: Xeris Biopharma Director Marla Persky Receives 50,000 Restricted Stock Units

Xeris Biopharma Holdings, Inc. Director Marla Persky was granted 50,000 restricted stock units, aligning her interests with shareholders.

Summary

• Marla Persky, a Director of Xeris Biopharma Holdings, Inc. (XERS), acquired 50,000 shares of common stock on June 4, 2025.
• These shares were granted as a restricted stock unit (RSU) award under the Company's 2018 Stock Option and Incentive Plan, with a transaction price of $0.
• The RSU award is set to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.
• Following this transaction, Ms. Persky directly beneficially owns 157,500 shares of common stock.
• Additionally, 6,370 shares are indirectly beneficially owned through the Marla Susan Persky Revocable Trust.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive event as it aligns management's interests with shareholders, but it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of 50,000 restricted stock units to Director Marla Persky aligns her financial interests with those of the company's shareholders.
• The award is part of the Company's 2018 Stock Option and Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The 50,000 restricted stock units granted to Director Marla Persky are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Industry Context

This transaction represents a routine equity compensation award to a director, a common practice across various industries, including biopharma, to incentivize long-term commitment and align leadership interests with shareholder value.

Stakeholder Impact

• Shareholders: The equity award to a director helps align management's long-term interests with shareholder value creation.

Next Steps

• Vesting of the 50,000 restricted stock units on or before June 4, 2026.

Key Dates

Keywords

Xeris Biopharma, XERS, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Director Compensation, Beneficial Ownership, Equity Award